Overview AI is speeding up drug discovery by analyzing large biological and chemical data in a short time.Deep learning and AI systems help design new drug mole ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced another major independent validation of its AI and machine learning (ML) capabilities in a ...

AI has fundamentally altered the feasibility of natural product discovery from fungal endophytes. Advances in genome sequencing, metabolomics, and systems biology have generated vast datasets, but ...

High-resolution analytical platforms, proteomics-driven workflows, and expanding CRO outsourcing reshape strategic priorities ...

According to Mordor Intelligence, the proteomics market size was valued at USD 29.92 billion in 2025 and projected to grow from USD 33.47 billion in 2026 to reach USD 58.66 billion by 2031, at a CAGR ...

Large language models (LLMs) can be broadly applied across multiple key stages in drug development: (1) Target identification and drug screening. Llama-Gram, GPCR LLM, and ProtChat systems effectively ...

The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...

AI and genetics are creating a 'seismic shift' in the pharmaceutical business, experts on Asian Financial Forum panel say ...

Aptamer Group plc, the developer of next-generation synthetic binders for the life sciences industry, today announced a new contract valued at up to £617,000 with a top-five pharmaceutical company.